Kalgutkar, Amit S <br/><br/>
Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.  [electronic resource] 

 -  Drug metabolism and disposition: the biological fate of chemicals  Sep 2011 
 - 1609-19 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1521-009X 
<br/><br/><label>Standard No.: </label>10.1124/dmd.111.040675  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Animals<br/>Biological Availability<br/>Biotransformation<br/>Bridged Bicyclo Compounds, Heterocyclic--pharmacokinetics<br/>Caco-2 Cells<br/>Cross-Over Studies<br/>Cytochrome P-450 Enzyme Inhibitors<br/>Cytochrome P-450 Enzyme System--metabolism<br/>Dogs<br/>Drug Evaluation, Preclinical<br/>Female<br/>Glucuronosyltransferase--metabolism<br/>HEK293 Cells<br/>Hepatocytes--drug effects<br/>Humans<br/>Intestinal Absorption<br/>Male<br/>Microsomes, Liver--enzymology<br/>Middle Aged<br/>Protein Binding<br/>Rats<br/>Rats, Sprague-Dawley<br/>Sodium-Glucose Transport Proteins--antagonists & inhibitors<br/>Young Adult